Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel medicine use of indirubin derivates

A derivative, the technology of indirubin, applied in the field of new medical applications of indirubin derivatives, can solve the problem of type 2 diabetes without effective treatment methods that meet clinical needs

Inactive Publication Date: 2007-12-05
安徽九鼎医药科技有限公司
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, there is still no effective treatment to meet the clinical needs in the treatment of type 2 diabetes.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel medicine use of indirubin derivates
  • Novel medicine use of indirubin derivates
  • Novel medicine use of indirubin derivates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1 Preparation of N-methyl-Δ3,3'-indoline-2,2'-dione tablets

[0064] N-methyl-Δ3,3'-indoline-2,2'-dione 25g

[0065] Microcrystalline Cellulose 101 70g

[0066] Proper amount of povidone K30

[0067] Micronized silica gel 1g

[0068] Magnesium Stearate 1g

[0069]

[0070] Makes 1000 pieces

[0071] Preparation method: After mixing the raw materials with microcrystalline cellulose, granulate with ethanol solution of povidone K30, dry and granulate, add micropowder silica gel and magnesium stearate, mix well and press into tablets.

[0072] Usage and dosage: 1-2 tablets each time, 2-3 times a day.

Embodiment 2

[0073] Example 2 Preparation of N-methyl-Δ3,3'-indoline-2,2'-dione capsules

[0074] N-methyl-Δ3,3'-indoline-2,2'-dione 25g

[0075] Microcrystalline Cellulose 102 70g

[0076] Micronized silica gel 1g

[0077]

[0078] Makes 1000 capsules

[0079] Preparation method: mix the raw materials and auxiliary materials evenly, and then fill the capsules.

[0080] Usage and dosage: 1-2 capsules each time, 2-3 times a day.

Embodiment 3

[0081] Example 3 Preparation of N-methyl-Δ3,3'-indoline-2,2'-dione and metformin hydrochloride compound tablet

[0082] N-methyl-Δ3,3'-indoline-2,2'-dione 25g

[0083] Metformin Hydrochloride 250g

[0084] Microcrystalline Cellulose 101 100g

[0085] Proper amount of povidone K30

[0086] Micronized silica gel 1g

[0087] Magnesium Stearate 1g

[0088]

[0089] Makes 1000 pieces

[0090] Preparation method: mix the raw materials with microcrystalline cellulose, granulate with ethanol solution of povidone K30, dry and granulate, add micropowder silica gel and magnesium stearate, mix well, and compress into tablets.

[0091] Usage and dosage: 1-2 tablets each time, 2-3 times a day.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the medicinal use of indirubin derivative, and is especially the application of indirubin derivative in preparing medicine for treating non-insulin dependent diabetes. Pharmacodynamic experiment shows that the indirubin derivative has the function of affecting the activity of PI3K component in insulin signal conducting passage, and can activate Akt and inhibit mTOR to promote the transfer of insulin signal and sensitize the peripheral tissue in utilizing insulin. The indirubin derivative is hopeful in developing medicine acting on insulin resistance to treat type II diabetes. The indirubin derivative and pharmaceutically acceptable supplementary material may be prepared into tablet, capsule or other oral preparation.

Description

1. Technical field [0001] The present invention relates to a new application of a known substance, in particular to a new medical application of the known compound, specifically a new medical application of an indirubin derivative. 2. Background technology [0002] Non-insulin-dependent diabetes mellitus is a major disease that endangers human health and causes death in the world. Its pathophysiological basis is relatively insufficient secretion and utilization of insulin, which leads to metabolic disorders and hyperglycemia. With the improvement of people's living standards, changes in diet structure, improvement of labor intensity, and increase in stress state, the incidence of diabetes all over the world is also increasing. According to the prediction of international authoritative diabetes epidemiology experts, by 2010, the global Diabetics will reach 240 million, and will increase to 300 million in 2050. The regions with the fastest growth in the number of patients wil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/404A61K31/443A61K9/20A61K9/48A61P3/10A61K31/155
Inventor 杨士友黄世福孙备
Owner 安徽九鼎医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com